IgG/IgM anti-HEV EIA

IgG/IgM anti-HEV antibody determination kit by EIA

Hepatitis E, a zoonotic disease, is caused by the hepatitis E virus (HEV). It mainly presents with acute hepatitis symptoms and is designated as a Category 4 infectious disease under the Infectious Diseases Law, requiring notification. Antibodies against HEV are produced when infected with HEV during the acute phase of hepatitis E. IgM anti-HEV antibody appears in the patient's serum and persist for 2 to 5 months after onset. IgG anti-HEV antibody appears somewhat later and persist for a longer period, and are an indicator of current or past infection.

This kit is a reagent for measuring IgG/IgM class anti-HEV antibodies based on the EIA method using recombinant HEV antigen protein as a solid-phase antigen and peroxidase-labeled anti-human IgG or anti-human IgM mouse monoclonal antibodies as secondary antibodies.

Application

Detection of IgG anti-HEV antibody or IgM anti-HEV antibody in human serum

Features


- 1. It is possible to detect IgG class anti-HEV antibodies, which indicate past HEV infection, and IgM class anti-HEV antibodies, which increase during the early stages of HEV infection.
- 2. This kit has high specificity and sensitivity, using recombinant HEV antigen as a solid-phase antigen.

Kit components

1.	Microplate coated with HEV antigen (8 wells/strip x	(12)1 plate
2.	Negative control	. 0.5 mL x 1 vial
3.	IgG positive control	. 0.5 mL x 1 vial
4.	IgM positive control	. 0.5 mL x 1 vial
5.	Sample diluent	50 mL x 1 vial
6.	Anti-IgG enzyme labeled monoclonal antibody	5 mL x 1 vial
7.	Anti-IgM enzyme labeled monoclonal antibody	5 mL x 1 vial
8.	Enzyme substrate	5 mL x 1 vial
9.	Reaction stopper	5 mL x 1 vial
10.	20x concentrated washing solution	50 mL x 1 vial
11.	Plate seal	3 sheets



Assay Principle



Assay Procedure and Well Arrangement

Well Arrangement		Blank	Blank Negative control Positive control		
	Wells	1A, (1B)	1C - 1F	1G - 12H	
1	Dilution of samples		No dilution needed	101 times dilution	
2	Addition of sample or controls				
	Negative control	_	50 μL	_	
	Positive control	_	50 μL	_	
	Diluted sample	_	_	50 <i>μ</i> L	
3	1st reaction	1 hr at 15 - 30°C			
4	Washing	5 times			
5	Addition of the enzyme labeled	_	50 μL	50 μL	
	monoclonal antibody				
6	2nd reaction	1 hr at 15 - 30°C			
7	Washing	5 times			
8	Addition of Enzyme substrate	50 <i>μ</i> L			
9	Enzyme reaction	30 min in the dark at 15 - 30°C			
10	Addition of Reaction stopper	50 μL			
11	Absorbance measurement	Main wavelength 450 nm, sub wavelength 630 nm			
12	Interpretation of results				

References

- 1) Mikhail S, Balayan MD: Int J Infect Dis 2 (2): 113-120, 1997.
- 2) Mizuo H, Suzuki K, Takikawa Y, et al: J Clin Microbiol 40: 3209-3218, 2002.
- 3) Takahashi M, Nishizawa T, Miyajima H, et al: J Gen Virol **84**: 851-862, 2003.
- 4) Takahashi M, Kusakai S, Mizuo H, et al: J Clin Microbiol 43: 49-56, 2005.

Product information

Product code	Product name	Package	Storage	Shelf life
1 Z 23	IgG/IgM anti-HEV EIA	96 tests	2-10°C	1 year



INSTITUTE OF IMMUNOLOGY CO., LTD.

1-1-10, Koraku, Bunkyo-ku, Tokyo 112-0004, JAPAN Tel +81-3-3814-4081 Fax +81-3-3814-5957

e-mail : info@tokumen.co.jp URL : https://www.tokumen.co.jp/en/

